4.5 Article

Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Scarification vaccination

Journal

VACCINE
Volume 26, Issue 23, Pages 2860-2872

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.03.044

Keywords

vaccinia; smallpox vaccine; E3L

Funding

  1. NIAID NIH HHS [AI 66501, AI66326, AI52347, R01 AI052347-02, U01 AI066326-03, U01 AI066326-01, U01 AI066326-02S1, U01 AI057303-05, R01 AI052347-04, R01 AI066501, U01 AI066326, R01 AI052347, U01 AI057303, R01 AI052347-01A1, U01 AI057303-02, U01 AI057303-03, U01 AI057303-01, R01 AI052347-03, U01 AI057303-04, R01 AI052347-05, U01 AI066326-02] Funding Source: Medline

Ask authors/readers for more resources

In this study, we evaluated the efficacy of vaccinia virus (VACV) containing mutations in the E3L virulence gene to protect mice against a lethal poxvirus challenge after vaccination by scarification. VACV strains with mutations in the E3L gene had significantly decreased pathogenicity, even in immune deficient mice, yet retained the ability to produce a potent Th1-dominated immune response in mice after vaccination by scarification, while protecting against challenge with wild type, pathogenic VACV. Initial experiments were done using the mouse-adapted, neurovirulent Western Reserve (WR) strain of vaccinia virus. Testing of the full E3L deletion mutation in the Copenhagen and NYCBH strains of VACV, which are more appropriate for use in humans, produced similar results. These results suggest that highly attenuated strains of VACV containing mutations in E3L have the potential for use as scarification administered vaccines. (c) 2008 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available